These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 27577530)

  • 1. Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies.
    Bundhun PK; Yanamala CM; Huang F
    BMC Cardiovasc Disord; 2016 Aug; 16(1):161. PubMed ID: 27577530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Sharma A; Garg A; Elmariah S; Drachman D; Obiagwu C; Vallakati A; Sharma SK; Lavie CJ; Mukherjee D; Waksman R; Stefanini GG; Feres F; Marmur JD; Helft G
    Prog Cardiovasc Dis; 2018; 60(4-5):500-507. PubMed ID: 29277295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials.
    Wang W; Liu J; Fang J; Liu Y; An T; Zou M; Cheng G
    Int J Cardiol; 2017 May; 235():73-86. PubMed ID: 28284499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of prolonging dual antiplatelet therapy on long-term prognosis of elderly patients with coronary heart disease complicated with diabetes mellitus undergoing drug-eluting stent implantation].
    Xu JJ; Zhu P; Song Y; Yuan DS; Jia SD; Zhao XY; Yao Y; Jiang L; Xu N; Li JX; Zhang Y; Song L; Gao LJ; Chen JL; Qiao SB; Yang YJ; Xu B; Gao RL; Yuan JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 May; 50(5):450-457. PubMed ID: 35589593
    [No Abstract]   [Full Text] [Related]  

  • 5. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse clinical outcomes associated with a low dose and a high dose of aspirin following percutaneous coronary intervention: a systematic review and meta-analysis.
    Bundhun PK; Janoo G; Teeluck AR; Huang WQ
    BMC Cardiovasc Disord; 2016 Sep; 16(1):169. PubMed ID: 27590185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Meta-analysis on safety and efficacy of dual antiplatelet therapy combining with proton pump inhibitors for patients after percutaneous coronary intervention].
    Che QQ; Wu Q; Liang YB; Sun RM; Lyu QW; Ma JL; Hu H; Lin X; Xu GL; Sun SG; Zhang C; Wang QY; Yu J; Bai F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Feb; 47(2):129-140. PubMed ID: 30818941
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
    Faggioni M; Baber U; Sartori S; Giustino G; Cohen DJ; Henry TD; Farhan S; Ariti C; Dangas G; Gibson M; Giacoppo D; Krucoff MW; Aquino M; Chandrasekhar J; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
    JACC Cardiovasc Interv; 2017 Apr; 10(7):645-654. PubMed ID: 28330641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the adverse clinical outcomes in patients with non-insulin treated type 2 diabetes mellitus and patients without type 2 diabetes mellitus following percutaneous coronary intervention: a systematic review and meta-analysis.
    Li N; Yang YG; Chen MH
    BMC Cardiovasc Disord; 2016 Nov; 16(1):238. PubMed ID: 27887590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials.
    Ning C; Ling F; Liu D; Zhi Z
    BMC Cardiovasc Disord; 2024 Mar; 24(1):166. PubMed ID: 38504170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy.
    Tarantini G; Nai Fovino L; Tellaroli P; Chieffo A; Barioli A; Menozzi A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Dominguez JF; Steffanon L; Presbitero P; Pucci E; Fraccaro C; Mauri J; Giustino G; Sardella G; Colombo A
    Int J Cardiol; 2016 Mar; 207():168-76. PubMed ID: 26803236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
    Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial.
    Franzone A; Piccolo R; Gargiulo G; Ariotti S; Marino M; Santucci A; Baldo A; Magnani G; Moschovitis A; Windecker S; Valgimigli M
    JAMA Cardiol; 2016 Oct; 1(7):795-803. PubMed ID: 27572001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
    Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
    Wang HY; Cai ZX; Yin D; Yang YJ; Song WH; Dou KF
    Am J Cardiol; 2021 Mar; 142():14-24. PubMed ID: 33285091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
    Grodzinsky A; Arnold SV; Wang TY; Sharma P; Gosch K; Jones PG; Bhatt DL; Steg PG; McGuire DK; Cohen DJ; Spertus JA; Chhatriwalla AK; Lind M; Graham G; Kosiborod M
    Am Heart J; 2016 Dec; 182():111-118. PubMed ID: 27914490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
    Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
    Bundhun PK; Huang F
    BMC Cardiovasc Disord; 2018 May; 18(1):78. PubMed ID: 29720092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.